Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biocon Biologics Secures Canadian Aflibercept Launch

Yesafili Biosimilar Rival To Eylea Can Launch In Canada By Mid-2025 Under Settlement

Executive Summary

Biocon has struck a deal with Bayer and Regeneron that will allow the global biosimilars player to launch its Yesafili biosimilar aflibercept rival to Eylea no later than 1 July 2025 in Canada.

You may also be interested in...

Biocon And Eris Strike Indian Deal Over Branded Formulations

Biocon has announced a deal with fellow Indian pharma firm Eris Lifesciences that involves the sale of its local metabolics, oncology, and critical care products while also transferring its employees.

Biocon Biologics: US Biosimilars Are A Marathon, Not A Sprint

As Biocon Biologics makes multiple moves to position its recently-integrated US biosimilars business for success, the firm’s chief commercial officer for advanced markets, Matt Erick, tells Generics Bulletin that US biosimilar competition is a “marathon” that is “not going to be won in the short term.”

Biocon Gets A New Group CEO As Aflibercept Approval Arrives

Biocon has named Peter Bains as its new group CEO, as the firm’s Biocon Biologics business confirmed that its aflibercept biosimilar to Eylea had become the first to receive a formal European approval.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts